Abstract
BackgroundSystemic inflammation has been implicated in cancer development and progression. This study examined the best cutoff value of erythrocyte sedimentation rate (ESR) in diffuse large B-cell lymphoma (DLBCL) patients.MethodsThe relationship between ESR and clinical characteristics was analyzed in 182 DLBCL patients from 2006 to 2017. The log-rank test, univariate analysis, and Cox regression analysis were applied to evaluate the relationship between ESR and survival. An ESR of more than 37.5 mm/hour was found to be the optimal threshold value for predicting prognosis.ResultsESR was associated with more frequent advanced Ann Arbor stage, poorer performance status, elevated lactate dehydrogenase level, the presence of B symptoms, high-risk International Prognostic Index (IPI 3–5), more extranodal involvement (ENI ≥2), non-germinal-center B-cell (non-GCB) subtypes, and more frequent Myc protein positivity. Shorter overall survival (OS) and progression-free survival (PFS) were found for patients with higher ESRs. Multivariate analysis demonstrated that ESR level is an independent prognostic factor of both OS and PFS. In addition, dynamic changes in ESR are valuable in assessing curative effect and predicting disease recurrence.ConclusionHigh ESR in DLBCL patients indicated unfavorable prognosis that may require alternative treatment regimens.
Highlights
Systemic inflammation has been implicated in cancer development and progression
Selection of patients According to the 2016 World Health Organization (WHO) classification, we reviewed the medical records of patients who were diagnosed with de novo diffuse large B-cell lymphoma (DLBCL) at the third affiliated hospital of Nantong University and affiliated Hospital of Jiangnan University from 2006 to 2017
In this study, we evaluated the prognostic value of erythrocyte sedimentation rate (ESR) in DLBCL patients
Summary
This study examined the best cutoff value of erythrocyte sedimentation rate (ESR) in diffuse large B-cell lymphoma (DLBCL) patients. Diffuse large B-cell lymphoma (DLBCL) is one of the most prevalent non-Hodgkin lymphomas (NHLs) which are heterogeneous both clinically and genetically. Despite recent progress in understanding the molecular biology of DLBCL, clinical risk factor models are still used to identify patients who are unlikely to be cured with current therapy. Comprehensive Cancer Network (NCCN-IPI), which is based on clinical parameters [2]. The NCCN-IPI is robust and confirmed to be reproducible [3,4,5], the link between the included clinical parameters and underlying biology or targeted treatment remains to be defined [6]. Alternative readily available prognostic characteristics with low clinical cost are greatly needed to improve risk assessment for individual patients
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
